- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
* RESEARCH HIGHLIGHT * 11 March 2020 By * Katharine H. Wrighton * Katharine H. Wrighton Many therapeutic antibodies can induce antibody-dependent cell-mediated cytotoxicity (ADCC), during
which an antibody-coated cell is lysed by immune cells such as natural killer (NK) cells. As these antibodies often target transmembrane receptors, which are readily endocytosed, Chew et al.
postulated that blocking endocytosis might increase receptor–therapeutic antibody binding and thus the efficacy of ADCC. Indeed, they now show that the antiemetic and antipsychotic drug
prochlorperazine (PCZ) can be repurposed to increase the clustering of receptors on the cell surface, enhancing ADCC in response to approved antibodies in the IgG1 subclass, such as
cetuximab and avelumab, in mouse models of cancer. ACCESS OPTIONS Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days
cancel any time Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Rent or buy this article Prices vary by article type from$1.95
to$39.95 Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: _Nature Reviews Drug Discovery_ 19, 237 (2020) _doi:
https://doi.org/10.1038/d41573-020-00041-z_ REFERENCES RELATED ARTICLES
